Pepcid


Also found in: Dictionary, Thesaurus, Wikipedia.
Related to Pepcid: Zantac, Pepcid ac

famotidine

Apo-Famotidine (CA), Gen-Famotidine (CA), Maalox H2 Acid Controller, Mylanta AR, Novo-Famotidine (CA), Nu-Famotidine (CA), Pepcid, Pepcid AC, Ulcidine (CA), Ultra Heartburn Relief (UK)

Pharmacologic class: Histamine2-receptor antagonist

Therapeutic class: Antiulcer drug

Pregnancy risk category B

Action

Blocks action of histamine at histamine2-receptor sites in gastric parietal cells, inhibiting gastric acid secretion and stabilizing pepsin

Availability

Gelcaps: 10 mg

Oral suspension: 40 mg/5 ml

Solution for injection: 10 mg/ml, 20 mg/50 ml of normal saline solution

Tablets: 10 mg, 20 mg, 40 mg

Tablets (chewable): 10 mg

Tablets (orally disintegrating): 20 mg, 40 mg

Indications and dosages

Active duodenal ulcers and benign gastric ulcers

Adults: 40 mg P.O. once daily at bedtime or 20 mg P.O. b.i.d. for up to 8 weeks

Prophylaxis of duodenal ulcers

Adults: 20 mg P.O. once daily at bedtime

Gastroesophageal reflux disease

Adults: 20 mg P.O. b.i.d. for up to 6 weeks. Maximum dosage is 40 mg b.i.d. for up to 12 weeks.

Children ages 1 to 16: 1 mg/kg P.O. daily in two divided doses, to a maximum of 40 mg b.i.d.

Infants ages 3 months to 1 year: 0.5 mg/kg P.O. b.i.d. for up to 8 weeks

Infants younger than age 3 months: 0.5 mg/kg P.O. once daily for up to 8 weeks

Gastric hypersecretory conditions (such as Zollinger-Ellison syndrome)

Adults: Initially, 20 mg P.O. q 6 hours, increased as needed to 160 mg q 6 hours

Hospitalized patients with pathologic hypersecretory conditions or ulcers; patients who can't take oral drugs

Adults: 20 mg I.V. q 12 hours

Prevention or treatment of heartburn, acid indigestion, and sour stomach (Pepcid AC only)

Adults: For prevention, 10 mg P.O. 1 hour before eating, or 10-mg chewable tablet 15 minutes before eating, to a maximum of 20 mg/24 hours for up to 2 weeks. For symptomatic treatment, 10 mg P.O. once or twice daily.

Dosage adjustment

• Renal impairment

Contraindications

• Hypersensitivity to drug or other histamine2-receptor antagonists

Precautions

Use cautiously in:
• renal impairment with prolonged QT interval and seizures (very rare)
• elderly patients
• pregnant or breastfeeding patients.

Administration

• Be aware that drug usually is given in one daily dose to patients with renal insufficiency.
• Give P.O. form with foods or liquids.
• Dilute I.V. form with 10 ml dextrose 5% in water or normal saline solution (100 ml) for I.V. piggyback administration.
• Deliver by I.V. push over 2 minutes or intermittent infusion over 30 minutes.
• Know that drug may cause transient irritation at I.V. site.

Adverse reactions

CNS: dizziness, headache, paresthesia, asthenia, fatigue, insomnia, somnolence, psychic disturbances

CV: palpitations, arrhythmias, AV block

GI: nausea, vomiting, diarrhea, constipation, dry mouth, anorexia, cholestatic jaundice, abdominal pain

GU: decreased libido

Hematologic: agranulocytosis, pancytopenia, leukopenia, thrombocytopenia (rare)

Hepatic: liver enzyme abnormalities, hepatitis

EENT: orbital edema, conjunctival redness, tinnitus

Musculoskeletal: musculoskeletal pain, muscle cramps, arthralgia

Respiratory: bronchospasm, interstitial pneumonia

Skin: flushing, acne, dry skin, rash, urticaria, alopecia, pruritus; epidermal necrolysis and Stevens-Johnson syndrome (very rare)

Other: altered taste, fever, pain at injection site, hypersensitivity reactions including anaphylaxis and angioedema

Interactions

Drug-diagnostic tests.Liver enzymes: altered levels

Patient monitoring

• Assess patient for GI signs and symptoms.
• Monitor blood urea nitrogen and creatinine levels in patients with renal impairment.

Monitor patient for prolonged QT interval and seizures, which have been reported very rarely in patients with impaired renal function whose famotidine dosage or dosing interval may not have been adjusted appropriately. Also monitor patient for arrhythmia and AV block.

Monitor patient for signs and symptoms of epidermal necrolysis, Stevens-Johnson syndrome, and hematologic or respiratory changes.

Patient teaching

• Tell patient that drug is most effective when taken at bedtime.
• Inform patient that pain relief may not begin until several days after therapy starts.

Instruct patient to take drug exactly as prescribed and to immediately report cardiovascular signs and symptoms, seizures, and hematologic or respiratory changes.
• Tell female patient to inform prescriber if she is pregnant or breastfeeding.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

Pepcid

(pĕp′sĭd)
A trademark for the drug famotidine.

Pepcid

a trademark for an H2 receptor antagonist used as antiulcer medication (famotidine).

Pepcid®

Famotidine, see there.
References in periodicals archive ?
Through our evolving PEPCID Tastemakers campaign, were able to forge strong relationships with our consumers who are die-hard food lovers and also heartburn sufferers, said Jennifer Cullen, Director of Marketing at Johnson & Johnson Consumer Inc.
Pepcid Complete curbed gastric acidity significantly faster than did the histamine-2 receptor antagonist and for a longer duration than did the antacid.
Medication options Famotidine (Pepcid, Pepcid AC), cimetidine (Tagarnet), ranitidine (Zantac), nizatidine (Axid).
Upon completion, J&J will own the joint venture's assets, including the exclusive rights to market OTC Pepcid, Mylanta, Mylicon, other local OTC brands and a manufacturing facility in Lancaster, PA.
On Wednesday, the federal regulators from the FDA announced that they received several complaints from J&J consumers, who contacted the company after finding that their Pepcid bottles included tablets from other products.
The Louisiana case involved pricing for the heartburn drug Pepcid when it was sold only by prescription.
It will be competing against J&J-Merck's products including the Pepcid line of nonprescription heartburn remedies and Mylanta antacids.
In April 1995, Johnson & Johnson/Merck received approval from the FDA to market Pepcid AC and subsequently launched the product the following June.
combination products Antiulcer Drugs - Tagamet, Zantac, Pepcid, Axid Analgesics - Darvocet/Wygesic, Talwin, Percodan, Percocet,
99 for 30 receptor tablets blocker Pepcid Histamine Famotidine, $10.
And, this year, the market was forever changed by the entries of Pepcid AC and Tagamet HB.
The concurrent use of H-2 blockers such as Tagamet, Zantac, Pepcid or Axid, may help to prevent the gastritis seen with NSAIDs, but they do not prevent NSAID-induced peptic ulcer disease.